Para‐methylthioamphetamine, a new amphetamine designer drug of abuse

  title={Para‐methylthioamphetamine, a new amphetamine designer drug of abuse},
  author={Douwe de Boer and Robert A. A. Maes and Toine C. G. Egberts},
  journal={Pharmacy World and Science},
A case study is described of a patient who was intoxicated after the intake of so‐called herbal stimulants. A visit to a physician after the intoxication prompted to this investigation and the case was examined for its direct cause. An interview with the patient revealed that the source of the herbal stimulants was a so‐called 'S‐5 tablet'. Information provided on the packings of the tablet only indicated the presence of natural alkaloids and vitamines. Toxicological analysis however proved… 
Bioanalysis of new designer drugs.
This review provides an overview of the developed bioanalytical and analytical methods, the matrices used, sample-preparation procedures, concentration of analytes in case of intoxication and also gives a résumé of immunoassay experiences.
4‐Methylthioamphetamine Increases Dopamine in the Rat Striatum and has Rewarding Effects In Vivo
Results show that MTA is able to increase extracellular striatal DA levels and that its administration has rewarding properties and these effects were observed at concentrations or doses that can be relevant to its use in human beings.
Comparative metabolism of the designer drug 4-methylthioamphetamine by hepatocytes from man, monkey, dog, rabbit, rat and mouse
It is shown that 4-methylthiobenzoic acid is the main metabolite formed from 4-MTA by human hepatocytes and also by the hepatocytes of the other tested species except the rat, which suggests that rabbit hepatocytes are more resistant to 4- MTA than the other species, which may be due to the more extensive metabolism.
A new trend in drugs-of-abuse; the 2C-series of phenethylamine designer drugs
The lack of observed intoxications may justify the absence of legal actions in the EU against phenethylamine designer drugs-of-abuse of the 2C-series, but EU authorities should promote the availability of relevant standards, validated assays and scientific knowledge regarding these drugs.
Study of the toxicological interactions between amphetamine designer drugs in the context of polydrug abuse
The impact of hyperthermia on the toxicity of amphetaminic mixtures and its applications in clinical practice and animal studies is investigated.


Comprehensive screening procedure for detection of stimulants, narcotics, adrenergic drugs, and their metabolites in human urine.
The GC-MS method was successfully used in doping control of urine samples during the 25th Olympic Games, July 1992, in Barcelona, Spain, and is described.
Evaluation of internal standards for the analysis of amphetamine and methamphetamine.
Thorough evaluation of the available options is presented here to assist laboratories in selection of the most appropriate internal standard for their individual needs and revealed several of the internal standards were not viable for monitoring ions typically associated with selected ion monitoring analysis of amphetamine and methamphetamine.
Neuroendocrine pharmacology of three serotonin releasers: 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butane (MBDB), 5-methoxy-6-methyl-2-aminoindan (MMAi) and p-methylthioamphetamine (MTA).
The results suggest that MBDB, MMAI and MTA can increase the secretion of several hormones, at least in part, through stimulation of serotonergic neurotransmission, however, these three 5-HT releasers seem to have effects on other mechanisms that can stimulate the release of some hormones.